Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brit Mollenhauer

Showing results (61-70 of 304) with videos related to

Pageof 31
Sort By:
Journal of Neurochemistry|January 5, 2022
Detection and quantification of Aβ-3-40 (APP669-711) in cerebrospinal fluidHans-Wolfgang Klafki, Oliver Wirths, Brit Mollenhauer, et al.
Plos One|April 27, 2016
A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal FluidNiels Kruse, Michael G Schlossmacher, Walter J Schulz-Schaeffer, et al.
The Journal of Biological Chemistry|July 31, 2012
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screeningMichael Bidinosti, Derya R Shimshek, Brit Mollenhauer, et al.
The Lancet. Neurology|April 15, 2019
CSF and blood biomarkers for Parkinson's diseaseLucilla Parnetti, Lorenzo Gaetani, Paolo Eusebi, et al.
The Analyst|August 13, 2016
Chemical profiling of cerebrospinal fluid by multiple reaction monitoring mass spectrometryChristina R Ferreira, Karen E Yannell, Brit Mollenhauer, et al.
Dementia and Geriatric Cognitive Disorders|February 14, 2008
Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-reviewMirko Bibl, Brit Mollenhauer, Hermann Esselmann, et al.
Sleep|July 2, 2021
Arousal characteristics in patients with Parkinson's disease and isolated rapid eye movement sleep behavior disorderAndreas Brink-Kjær, Matteo Cesari, Friederike Sixel-Döring, et al.
Annals of Neurology|September 8, 2015
Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's diseaseAngela Pyle, Rebecca Brennan, Marzena Kurzawa-Akanbi, et al.
NPJ Parkinson'S Disease|May 6, 2026
The epitranscriptomic m6A RNA modification modulates the synapse in ageing and in a mouse model of synucleinopathyAvika Chopra, Mary Xylaki, Fanzheng Yin, et al.
Neurology|March 24, 2017
Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson diseaseLynn Rochester, Brook Galna, Sue Lord, et al.
Pageof 31

Showing results (61-70 of 304) with videos related to

Sort By:
Pageof 31
Journal of Neurochemistry|January 5, 2022
Detection and quantification of Aβ-3-40 (APP669-711) in cerebrospinal fluidHans-Wolfgang Klafki, Oliver Wirths, Brit Mollenhauer, et al.
Plos One|April 27, 2016
A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal FluidNiels Kruse, Michael G Schlossmacher, Walter J Schulz-Schaeffer, et al.
The Journal of Biological Chemistry|July 31, 2012
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screeningMichael Bidinosti, Derya R Shimshek, Brit Mollenhauer, et al.
The Lancet. Neurology|April 15, 2019
CSF and blood biomarkers for Parkinson's diseaseLucilla Parnetti, Lorenzo Gaetani, Paolo Eusebi, et al.
The Analyst|August 13, 2016
Chemical profiling of cerebrospinal fluid by multiple reaction monitoring mass spectrometryChristina R Ferreira, Karen E Yannell, Brit Mollenhauer, et al.
Dementia and Geriatric Cognitive Disorders|February 14, 2008
Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-reviewMirko Bibl, Brit Mollenhauer, Hermann Esselmann, et al.
Sleep|July 2, 2021
Arousal characteristics in patients with Parkinson's disease and isolated rapid eye movement sleep behavior disorderAndreas Brink-Kjær, Matteo Cesari, Friederike Sixel-Döring, et al.
Annals of Neurology|September 8, 2015
Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's diseaseAngela Pyle, Rebecca Brennan, Marzena Kurzawa-Akanbi, et al.
NPJ Parkinson'S Disease|May 6, 2026
The epitranscriptomic m6A RNA modification modulates the synapse in ageing and in a mouse model of synucleinopathyAvika Chopra, Mary Xylaki, Fanzheng Yin, et al.
Neurology|March 24, 2017
Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson diseaseLynn Rochester, Brook Galna, Sue Lord, et al.
Pageof 31